Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the therapeutic effect of fumaric acid esters
(Fumaderm®) in the treatment of Cutaneous Lupus Erythematosus with respect to proportion of
responders based on the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI)
activity score for skin lesions at baseline and after 24 weeks of treatment or at the latest
assessment for patients who withdrew prematurely (Last Observation Carried Forward, LOCF).